Pliant Therapeutics (MUN:9PT) - Aktienkurs, Nachrichten und Analyse

9PT Aktienübersicht

A clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.

Über das Unternehmen

9PT grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 43.09%

Risikoanalyse

Aktien sind hochgradig illiquide

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 8.9% pro Jahr sinken.

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Pliant Therapeutics, Inc. Wettbewerber

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€275.8m

Cantourage Group

XTRA:HIGH

€84.8m

Bayer

XTRA:BAYN

€25.7b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Pliant Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	US$32.00
52-Wochen-Hoch	US$33.00
52-Wochen-Tief	US$3.98
Beta	1.38
11 Monat Veränderung	0%
3 Monate Veränderung	-0.62%
1 Jahr Veränderung	420.33%
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	48.15%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	9PT	DE Pharmaceuticals	DE Markt
7D	0%	-4.7%	0.09%
1Y	420.3%	-18.7%	3.1%

Rendite im Vergleich zur Industrie: 9PT übertraf die Branche German Pharmaceuticals, die im vergangenen Jahr eine Rendite von -20.1 erzielte.

Rendite vs. Markt: 9PT übertraf den Markt German, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is 9PT's price volatile compared to industry and market?
9PT volatility
9PT Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.5%

Stabiler Aktienkurs: 9PTDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von 9PT im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2015	124	Bernard Coulie	pliantrx.com

Pliant Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Pliant Therapeutics im Vergleich zum Marktanteil des Unternehmens?
9PT grundlegende Statistiken
Marktanteil	€1.52b
Gewinn(TTM)	-€111.91m
Umsatz(TTM)	€8.79m

172.6x

Kurs-Umsatz-Verhältnis

-13.6x

Kurs-Gewinn-Verhältnis

Ist 9PT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
9PT Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$9.69m
Kosten der Einnahmen	US$0
Bruttogewinn	US$9.69m
Sonstige Ausgaben	US$133.01m
Umsatz	-US$123.32m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.08
Bruttomarge	100.00%
Nettogewinnspanne	-1,273.32%
Schulden/Eigenkapital-Verhältnis	3.2%

Wie hat sich 9PT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

9PT Aktienübersicht

Belohnungen

Risikoanalyse

Pliant Therapeutics, Inc. Wettbewerber

XTRA:DMP

€2.0b

XTRA:PSG

€275.8m

XTRA:HIGH

€84.8m

XTRA:BAYN

€25.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Recent updates

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

Insufficient new directors

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings released: US$0.65 loss per share (vs US$0.75 loss in 3Q 2021)

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.64 loss in 2Q 2021)

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.64 loss in 1Q 2021)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expected 2022 Milestones

Third quarter 2021 earnings released: US$0.75 loss per share (vs US$0.47 loss in 3Q 2020)

Pliant Therapeutics, Inc. Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.64 loss per share

Pliant Therapeutics, Inc. Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €28.60

Investor sentiment improved over the past week

New 90-day high: €26.40

Pliant Therapeutics, Inc. Announces Appointment of David Pyott to Board of Directors

Investor sentiment improved over the past week

New 90-day high: €24.21

Pliant Therapeutics Appoints Mike Ouimette as General Counsel and Corporate Secretary

New 90-day low: €19.00

Pliant Therapeutics, Inc. announced that it expects to receive $45 million in funding

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Pliant Therapeutics, Inc.'s Grundlagenzusammenfassung

172.6x

-13.6x

Erträge &amp; Einnahmen

Erträge & Einnahmen